$RNAC
Cartesian Therapeutics, Inc.

2019 Q2 Form 10-Q Financial Statement

#000145368719000053 Filed on May 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $13.00K $10.00K $903.0K
YoY Change 5211.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.110M $4.510M $5.150M
YoY Change -5.73% -3.43% -9.17%
% of Gross Profit
Research & Development $12.13M $7.353M $10.26M
YoY Change -15.78% -33.99% -24.67%
% of Gross Profit
Depreciation & Amortization $200.0K $181.0K $190.0K
YoY Change -50.0% -9.5% 5.56%
% of Gross Profit
Operating Expenses $16.25M $11.87M $15.40M
YoY Change -13.43% -24.96% -20.17%
Operating Profit -$16.24M -$11.86M
YoY Change -13.5% -25.02%
Interest Expense $400.0K $396.0K -$150.0K
YoY Change 9.59% 13.14% 15.38%
% of Operating Profit
Other Income/Expense, Net $5.000K -$69.00K $0.00
YoY Change -37.5% -100.0%
Pretax Income -$16.39M -$12.07M -$14.65M
YoY Change -12.82% -24.04% -25.03%
Income Tax
% Of Pretax Income
Net Earnings -$16.39M -$12.07M -$14.65M
YoY Change -12.78% -24.01% -25.04%
Net Earnings / Revenue -126107.69% -120740.0% -1622.48%
Basic Earnings Per Share
Diluted Earnings Per Share -$365.4K -$313.9K -$652.6K
COMMON SHARES
Basic Shares Outstanding 44.79M shares 44.73M shares 22.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.70M $48.40M $37.40M
YoY Change -37.01% -41.76% -61.28%
Cash & Equivalents $30.20M $32.17M $37.40M
Short-Term Investments $11.50M $16.20M $0.00
Other Short-Term Assets $2.800M $76.00K $80.00K
YoY Change 7.69% -96.0% -96.19%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $44.45M $59.53M $42.08M
YoY Change -35.43% -39.68% -57.36%
LONG-TERM ASSETS
Property, Plant & Equipment $1.620M $1.799M $2.127M
YoY Change -24.19% -13.96% 1.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $300.0K
YoY Change -100.0% -100.0%
Total Long-Term Assets $2.498M $2.954M $2.406M
YoY Change -45.72% 22.07% -0.58%
TOTAL ASSETS
Total Short-Term Assets $44.45M $59.53M $42.08M
Total Long-Term Assets $2.498M $2.954M $2.406M
Total Assets $46.95M $62.48M $44.48M
YoY Change -36.07% -38.2% -56.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.463M $693.0K $1.100M
YoY Change 37.67% -56.85% -31.51%
Accrued Expenses $5.789M $8.500M $11.70M
YoY Change -43.16% -0.93% 36.36%
Deferred Revenue $1.023M $959.0K $959.0K
YoY Change -46.66% 21.86% 21.86%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $21.50M $21.50M $21.40M
YoY Change
Total Short-Term Liabilities $31.91M $33.05M $35.14M
YoY Change 129.7% 201.16% 220.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $0.00 $801.0K $938.0K
YoY Change -100.0% -33.31% -21.9%
Total Long-Term Liabilities $0.00 $801.0K $938.0K
YoY Change -100.0% -33.31% -21.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.91M $33.05M $35.14M
Total Long-Term Liabilities $0.00 $801.0K $938.0K
Total Liabilities $46.89M $47.66M $49.90M
YoY Change -4.64% 0.44% 1.25%
SHAREHOLDERS EQUITY
Retained Earnings -$308.9M -$335.8M -$280.4M
YoY Change 24.96% 56.14% 29.28%
Common Stock $5.000K $5.000K $3.000K
YoY Change 66.67% 66.67% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.00K $14.82M -$5.418M
YoY Change
Total Liabilities & Shareholders Equity $46.95M $62.48M $44.48M
YoY Change -36.07% -38.2% -56.0%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$16.39M -$12.07M -$14.65M
YoY Change -12.78% -24.01% -25.04%
Depreciation, Depletion And Amortization $200.0K $181.0K $190.0K
YoY Change -50.0% -9.5% 5.56%
Cash From Operating Activities -$7.200M -$20.24M -$12.75M
YoY Change -57.57% 50.94% 0.63%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 -$360.0K
YoY Change -96.3% -100.0% 140.0%
Acquisitions
YoY Change
Other Investing Activities $4.850M -$16.12M $0.00
YoY Change -74.41% -1514.04% -100.0%
Cash From Investing Activities $4.850M -$16.12M -$380.0K
YoY Change -74.04% -1805.71% -106.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.94M
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities 370.0K $31.11M 80.00K
YoY Change 19.35% 60894.12% -98.41%
NET CHANGE
Cash From Operating Activities -7.200M -$20.24M -12.75M
Cash From Investing Activities 4.850M -$16.12M -380.0K
Cash From Financing Activities 370.0K $31.11M 80.00K
Net Change In Cash -1.980M -$5.230M -13.05M
YoY Change -198.02% -57.8% 752.94%
FREE CASH FLOW
Cash From Operating Activities -$7.200M -$20.24M -$12.75M
Capital Expenditures -$10.00K $0.00 -$360.0K
Free Cash Flow -$7.190M -$20.24M -$12.39M
YoY Change -56.95% 48.81% -1.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001453687
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44788025 shares
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
SELECTA BIOSCIENCES INC
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22471776 shares
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44788025 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22471776 shares
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44788025 shares
CY2018Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2018Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000 USD
CY2019Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
344100 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2019Q1 selb Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current
CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent
32452000 USD
CY2018Q4 selb Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current
CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent
37403000 USD
CY2019Q1 us-gaap Short Term Investments
ShortTermInvestments
16244000 USD
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10832000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4673000 USD
CY2019Q1 us-gaap Assets Current
AssetsCurrent
59528000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
42076000 USD
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1799000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2127000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1155000 USD
CY2019Q1 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
0 USD
CY2018Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
279000 USD
CY2019Q1 us-gaap Assets
Assets
62482000 USD
CY2018Q4 us-gaap Assets
Assets
44482000 USD
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
693000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1100000 USD
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8500000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11700000 USD
CY2019Q1 us-gaap Loans Payable Current
LoansPayableCurrent
21466000 USD
CY2018Q4 us-gaap Loans Payable Current
LoansPayableCurrent
21385000 USD
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1428000 USD
CY2019Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
959000 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
959000 USD
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
33046000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35144000 USD
CY2019Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0 USD
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
34000 USD
CY2019Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13816000 USD
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13818000 USD
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
801000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
904000 USD
CY2019Q1 us-gaap Liabilities
Liabilities
47663000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
49900000 USD
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
311824000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
279539000 USD
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292477000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-280403000 USD
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4533000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4557000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14819000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-5418000 USD
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62482000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44482000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10000 USD
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7353000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11139000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4513000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4674000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
11866000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
15813000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11856000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15813000 USD
CY2019Q1 us-gaap Investment Income Net
InvestmentIncomeNet
277000 USD
CY2018Q1 us-gaap Investment Income Net
InvestmentIncomeNet
288000 USD
CY2019Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30000 USD
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13000 USD
CY2019Q1 us-gaap Interest Expense
InterestExpense
396000 USD
CY2018Q1 us-gaap Interest Expense
InterestExpense
350000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-69000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-12074000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15888000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
22000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
19000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 USD
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12050000 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15866000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-12074000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15888000 USD
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12074000 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15888000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38447319 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22345523 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-5418000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
20000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
145000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30942000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
22000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-12074000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14819000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
51814000 USD
CY2018Q1 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
1830000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
53000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1153000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
19000 USD
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15888000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
38984000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-12074000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15888000 USD
CY2019Q1 us-gaap Depreciation
Depreciation
181000 USD
CY2018Q1 us-gaap Depreciation
Depreciation
169000 USD
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
47000 USD
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
32000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1180000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1153000 USD
CY2019Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
189000 USD
CY2018Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
177000 USD
CY2019Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-70000 USD
CY2018Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5712000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-417000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-407000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
180000 USD
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2000 USD
CY2018Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3618000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
404000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20240000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13409000 USD
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0 USD
CY2018Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
15045000 USD
CY2019Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
18188000 USD
CY2018Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
13908000 USD
CY2019Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
1992000 USD
CY2018Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
192000 USD
CY2019Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
77000 USD
CY2018Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16119000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
945000 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30942000 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
145000 USD
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
20000 USD
CY2018Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
51000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31107000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
51000 USD
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
22000 USD
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
19000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5230000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12394000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37682000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71027000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32452000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58633000 USD
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
312000 USD
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
261000 USD
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
142000 USD
CY2019Q1 selb Equity Offering Costs In Accrued Liabilities
EquityOfferingCostsInAccruedLiabilities
10000 USD
CY2018Q1 selb Equity Offering Costs In Accrued Liabilities
EquityOfferingCostsInAccruedLiabilities
0 USD
CY2019Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
2000 USD
CY2018Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
3000 USD
CY2019Q1 us-gaap Short Term Investments
ShortTermInvestments
16200000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32500000 USD
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292500000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-280400000 USD
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates<span style="font-family:inherit;font-size:10pt;"> </span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, accounting for stock-based compensation and estimating accrued research and development expenses. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div>
CY2019Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32173000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58228000 USD
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
279000 USD
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
76000 USD
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0 USD
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
329000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32452000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58633000 USD
CY2019Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentrations of Credit Risk and Off‑Balance Sheet RiskFinancial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term deposits and investments, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars.
CY2019Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2019Q1 selb Availablefor Sale Debt Securities Number Of Positions
AvailableforSaleDebtSecuritiesNumberOfPositions
15 position
CY2019Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
16244000 USD
CY2019Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
16243000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
0 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
0 USD
CY2019Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
16243000 USD
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 USD
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2019Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
16244000 USD
CY2019Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 position
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-12074000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15888000 USD
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38447319 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22345523 shares
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4935361 shares
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2834467 shares
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6061000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6679000 USD
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4262000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4552000 USD
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1799000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2127000 USD
CY2019Q1 us-gaap Depreciation
Depreciation
200000 USD
CY2018Q1 us-gaap Depreciation
Depreciation
200000 USD
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1875000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2497000 USD
CY2019Q1 selb Accrued Rent And Lease Incentive Payable Current
AccruedRentAndLeaseIncentivePayableCurrent
0 USD
CY2018Q4 selb Accrued Rent And Lease Incentive Payable Current
AccruedRentAndLeaseIncentivePayableCurrent
117000 USD
CY2019Q1 selb Accrued Collaborationand Licensing
AccruedCollaborationandLicensing
831000 USD
CY2018Q4 selb Accrued Collaborationand Licensing
AccruedCollaborationandLicensing
1222000 USD
CY2019Q1 selb Accrued Patent Fees Current
AccruedPatentFeesCurrent
510000 USD
CY2018Q4 selb Accrued Patent Fees Current
AccruedPatentFeesCurrent
736000 USD
CY2019Q1 selb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3826000 USD
CY2018Q4 selb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5344000 USD
CY2019Q1 selb Accrued Audit Fees Current
AccruedAuditFeesCurrent
920000 USD
CY2018Q4 selb Accrued Audit Fees Current
AccruedAuditFeesCurrent
994000 USD
CY2019Q1 selb Accrued Grant Refund Current
AccruedGrantRefundCurrent
175000 USD
CY2018Q4 selb Accrued Grant Refund Current
AccruedGrantRefundCurrent
175000 USD
CY2019Q1 us-gaap Interest Payable Current
InterestPayableCurrent
109000 USD
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
106000 USD
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
254000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
509000 USD
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8500000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11700000 USD
CY2019Q1 selb Clinical Operations Prepaid Expense Current
ClinicalOperationsPrepaidExpenseCurrent
9916000 USD
CY2018Q4 selb Clinical Operations Prepaid Expense Current
ClinicalOperationsPrepaidExpenseCurrent
3550000 USD
CY2019Q1 us-gaap Prepaid Insurance
PrepaidInsurance
222000 USD
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
433000 USD
CY2019Q1 us-gaap Prepaid Rent
PrepaidRent
192000 USD
CY2018Q4 us-gaap Prepaid Rent
PrepaidRent
188000 USD
CY2019Q1 selb Service Agreements
ServiceAgreements
426000 USD
CY2018Q4 selb Service Agreements
ServiceAgreements
422000 USD
CY2019Q1 us-gaap Other Assets Current
OtherAssetsCurrent
76000 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
80000 USD
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10832000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4673000 USD
CY2019Q1 selb Operating Lease Remaining Lease Term
OperatingLeaseRemainingLeaseTerm
P15M
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.100
CY2017Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
5100 sqft
CY2019Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000 USD
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
341000 USD
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
203000 USD
CY2019Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000 USD
CY2019Q1 us-gaap Lease Cost
LeaseCost
552000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1119000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
375000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1494000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
66000 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1428000 USD
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1428000 USD
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1428000 USD
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
363000 USD
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1900000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1482000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
375000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1857000 USD
CY2019Q1 selb Debt Instrument Event Of Default Minimum Assets Trigger
DebtInstrumentEventOfDefaultMinimumAssetsTrigger
300000 USD
CY2019Q1 selb Debt Instrument Event Of Default Minimum Amount In Excess Of Indebtedness Trigger
DebtInstrumentEventOfDefaultMinimumAmountInExcessOfIndebtednessTrigger
300000 USD
CY2019Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.50
CY2019Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.50
CY2019Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
30900000 USD
CY2016Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
64500000 USD
CY2016Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
10126118 shares
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
44788025 shares
CY2019Q1 selb Votes Per Shareof Common Stock
VotesPerShareofCommonStock
1 vote
CY2019Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0 USD
CY2019Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8947568 shares
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5951523 shares
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1180000 USD
CY2018Q4 selb Contractwith Customer Liability Other
ContractwithCustomerLiabilityOther
2126000 USD
CY2019Q1 selb Contractwith Customer Liability Other Increase From Cash Receipts
ContractwithCustomerLiabilityOtherIncreaseFromCashReceipts
0 USD
CY2019Q1 selb Contractwith Customer Liability Other Revenue Recognized
ContractwithCustomerLiabilityOtherRevenueRecognized
493000 USD
CY2019Q1 selb Contractwith Customer Liability Other
ContractwithCustomerLiabilityOther
1633000 USD
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
16903000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1153000 USD
CY2016Q4 selb License And Option Agreement Number Of Additional Targets For Which Other Party May Exercise Options For Additional Licenses
LicenseAndOptionAgreementNumberOfAdditionalTargetsForWhichOtherPartyMayExerciseOptionsForAdditionalLicenses
4 target
CY2019Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
8600000 USD
CY2019Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.089
CY2019Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2018Q4 selb Contractwith Customer Liability Deferred Revenue
ContractwithCustomerLiabilityDeferredRevenue
14777000 USD
CY2019Q1 selb Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts
ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts
8000 USD
CY2019Q1 selb Contractwith Customer Liability Deferred Revenue Revenue Recognized
ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized
10000 USD
CY2019Q1 selb Contractwith Customer Liability Deferred Revenue
ContractwithCustomerLiabilityDeferredRevenue
14775000 USD
CY2019Q1 selb Contractwith Customer Liability Increase From Cash Receipts
ContractwithCustomerLiabilityIncreaseFromCashReceipts
8000 USD
CY2019Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
503000 USD
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
16408000 USD
CY2019Q1 selb Contractwith Customer Liability Other Current
ContractwithCustomerLiabilityOtherCurrent
800000 USD
CY2019Q1 selb Contractwith Customer Liability Other Noncurrent
ContractwithCustomerLiabilityOtherNoncurrent
800000 USD
CY2019Q1 selb Reimbursement Invoice
ReimbursementInvoice
500000 USD
CY2019Q1 us-gaap Other Liabilities
OtherLiabilities
1600000 USD
CY2019Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
22188706 shares
CY2019Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.50
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33300000 USD
CY2019Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2019Q1 selb Defined Contribution Plan Employers Matching Contribution Vesting Period
DefinedContributionPlanEmployersMatchingContributionVestingPeriod
P4Y
CY2018Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 USD

Files In Submission

Name View Source Status
0001453687-19-000053-index-headers.html Edgar Link pending
0001453687-19-000053-index.html Edgar Link pending
0001453687-19-000053.txt Edgar Link pending
0001453687-19-000053-xbrl.zip Edgar Link pending
adonohue-employmentagr.htm Edgar Link pending
ekoganemploymentagreem.htm Edgar Link pending
exhibit31103312019.htm Edgar Link pending
exhibit31203312019.htm Edgar Link pending
exhibit32103312019.htm Edgar Link pending
exhibit32203312019.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
selb-20190331.xsd Edgar Link pending
selb-20190331_cal.xml Edgar Link unprocessable
selb-20190331_def.xml Edgar Link unprocessable
selb-20190331_lab.xml Edgar Link unprocessable
selb-20190331_pre.xml Edgar Link unprocessable
selectabiosciences10-q.htm Edgar Link pending
selectabiosciences10-q_htm.xml Edgar Link completed
Show.js Edgar Link pending